Aurinia Pharmaceuticals Inc

Jim Cramer says pandemic stocks are back in fashion, but investors should approach with caution.

The persistent gulf between big cap growth stocks and downtrodden secondary stocks like biotechs is showing signs of narrowing.

Several companies were losing ground Monday even as stocks hit fresh record highs.

Knowing what's on your shopping list ahead of time is key to taking advantage of volatile markets.

As September gets established, James "Rev Shark" Deporre is keeping his eyes on these names.

As COVID re-emerges, Jim Cramer says it's time to look at companies that flourish in an economy that might get worse before it gets better.

Jim Cramer says that between stimulus programs and vaccines, it looks like the American economy has weathered the worst of COVID.

Jim Cramer says if you focus on what's going right, you'll sleep better and do a lot better with your money, too.

Jim Cramer weighs in on Waste Management, Weight Watchers, Centene, Aurinia Pharmaceuticals, Activision Blizzard, AbbVie, Cronos Group and more.

Jim Cramer says Netflix serves as a reminder to all investors exactly how powerful the subscriber business is.

Jim Cramer takes a closer look at IBM, Nike, Newmont Mining, U.S. Silica Holdings, Aurinia Pharmaceuticals, CenturyLink, Exxon Mobil and more.

Jim Cramer likes Park Hotels and Resorts and Aurinia Pharmaceuticals, but he's bearish on GOL Intelligent Air and Gamestop.

Will the benign backdrop continue next week? Cramer has a defensive game plan, in case earnings chill the market.

The stock market looks overbought.

Jim Cramer says the earnings results we get this week will determine where stocks are headed for the rest of the quarter.

Akebia is a lot like other small biotech companies with quality management teams executing well but ignored by investors for reasons that don't really make much sense fundamentally.

Jim Cramer is bullish on Delta, Barracuda Networks, STMicroelectronics, UnitedHealth Group.

This week the markets fell back on earnings -- like Adobe -- and remained afloat, says Jim Cramer.

Aurinia executives don't manage the business to serve the interest of traders and their desire to flip the stock for a few bucks' profit.

The gold miner has yet to benefit from rising gold prices but some restructuring could happen just in time.

How can we find reasonably priced stocks right now? By staying off the beaten path. Let me explain.

Revisiting three attractive biotech companies that reported solid Q3 results last week.

Here's why and how I'm putting some of my dry powder to work as the market sells off.

These names could benefit if a significant M&A wave washes across the biotech sector in the quarters ahead.

Aurinia makes a great covered-call play as M&A in biotech heats up.

Let's take a look at Exelixis and Aurinia Pharmaceuticals and the bigger economic picture.

These go-to technology names prevent the indexes from really breaking down, while elevating sentiment. Here's why that's a problem for traders.

With all these indicators oversold, it is possible for the market to not rally but also break down badly.

Here's a trade idea for Aurinia Pharmaceuticals.

Despite the choppy action, I've been positioning in two trades that I think will develop over the next few weeks.

The prospects for this trio are better than in the current year, which has been rough on all three.

It has been a mistake to trust momentum to last in this environment.

There's a bright spot, but it needs to be sustained.

Here are three names I have added to in May.

There is a high level of risk that the market rolls over again, but that risk will be minimized if we have some better chart development in the days ahead.

We still have this issue with headline risk that is going to make it hard to navigate.

Prices look like they can bounce further to the upside in the short-run but the longer-term picture is problematic.

Yet there's good relative strength in biotech, growth, cannabis, small-caps, and other sectors that have been the biggest laggards.

The retail goliath has more plans for its brick-and-mortar operations.

The retailer is making a swift change to a previously lenient policy.

Netflix announces major price hikes in its membership tiers and its shares skyrocket.